Seminars in Oncology
Volume 34 , Pages S1-S2 , December 2007

Introduction

  • Hagop M. Kantarjian (Guest Editor)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Hagop M. Kantarjian, MD, Department of Leukemia, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 0428, Houston, TX 77030
    • Dr Kantarjian has received research grant support from Novartis, Bristol Myers Squibb, and MGI Pharma.

References 

  1. Leukemia and Lymphoma Society. Leukemia facts and statistics. Last update: 2007. http://www.leukemia-lymphoma.org/all_page?item_id=9346#_survival(accessed February 8, 2007)
  2. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1:1010–1013
  3. Markert ML. Purine nucleoside phosphorylase deficiency. Immunodef Rev. 1991;3:45–81
  4. Viegas TX, Omura GA, Stoltz RR, et al. Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2000;40:410–420
  5. Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—A novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1:1199–1210
  6. Miles RW, Tyler PC, Furneaux RH, et al. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 1998;37:8615–8621
  7. Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel. 2004;7:243–247
  8. Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor—BCX-1777. Int Immunopharmacol. 2003;3:879–887
  9. Thomas DA, Wierda W, Faderl S, et al. Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies. Blood. 2003;102(suppl 1):512b;(abstr 4772)
  10. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106:4253–4260
  11. Furman RR, Gore L, Ravandi F, et al. Forodesine IV (BCX-1777) is clinically active in relapsed/refractory T-cell leukemia: Results of a phase II study (interim report). Blood. 2006;108(suppl 1):524a;(abstr 1851)
  12. Duvic M, Forero-Torres A, Foss F. Oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I/II study. Blood. 2006;108(suppl 1):698a;(abstr 2467)
  13. Duvic M, Foss FM, Olsen EA, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Blood. 2004;104(suppl 1):683a;(abstr 2491)
  14. Ritchie E, Gore L, Roboz G, et al. Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia. Blood. 2006;108(suppl 1):533a;(abstr 1881)
  15. Furman RR, Gandhi VV, Bennett JC, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood. 2004;104(suppl 1):750a;(abstr 2743)

PII: S0093-7754(07)00226-6

doi: 10.1053/j.seminoncol.2007.11.007

Seminars in Oncology
Volume 34 , Pages S1-S2 , December 2007

Article Tools